We could not find any results for:
Make sure your spelling is correct or try broadening your search.
DJ CFA SOURCE: SEC 13F-HR FILER: Fidelity Management & Research Co. QUARTER ENDED: 09/30/2013 SEC RECEIVED: 11/14/2013 Up to 200 of the largest eliminated positions of Fidelity Management...
DJ CFA SOURCE: SEC 13F-HR FILER: Fidelity Management & Research Co. QUARTER ENDED: 09/30/2013 SEC RECEIVED: 11/14/2013 Up to 200 of the largest purchases of Fidelity Management &...
- Oral PRX-106 for immune mediated disorders - PRX-110 for Cystic Fibrosis (CF) - PRX-107 for emphysema due to hereditary alpha1-antitrypsin deficiency CARMIEL, Israel, June 20, 2013 (GLOBE...
CARMIEL, Israel, June 19, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that it has entered into a supply and technology transfer agreement...
CARMIEL, Israel, June 12, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), will be hosting an analyst event on Thursday, June 20, 2013 at 8:00 AM EDT in New York...
CARMIEL, Israel, May 29, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), today announced that senior management will present at three upcoming healthcare...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | -0.39 | -48.75 | 0.8 | 0.8 | 0.4 | 24555 | 0.64598014 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions